Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
JPMA Exec Urges Immediate Action on Inflation Pressures as Budget Talks Loom
Japan Pharmaceutical Manufacturers Association (JPMA) Director General Kenshi Kinoshita on November 13 renewed the trade group’s call for urgent measures to address inflationary pressures facing the pharmaceutical industry, saying that countermeasures “can no longer be delayed” as year-end budget debates…
To read the full story
Related Article
- JPMA Exec Renews Call for Simpler Drug Pricing System
December 19, 2025
- JPMA Chief Renews Call for Reflecting Inflation and Wage Hikes in Drug Pricing
October 17, 2025
ORGANIZATION
- Labor Group Chief Pushes Fundamental Drug Pricing Reform Ahead of Honebuto
April 8, 2026
- Drug Makers Step Up Self-Inspections for Supply Stability: FPMAJ Survey
April 8, 2026
- Pharma Labor Group Sees Wage Hikes in Low 4% Range as Talks Continue
April 7, 2026
- Generic Use Rate Hits 90% for First Time in October-December: JGA
April 7, 2026
- JPMA to Prepare Response to US “MFN” Policy under New Strategy Unit
April 2, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…